10th Annual Champalimaud Research Symposium, Hyderabad
2017 marks the 10th anniversary of a partnership that the Champalimaud Foundation is extremely proud of: the one between our institution and LV Prasad Eye Institution. And what better way to commemorate this special day than to share yet another opportunity to exchange knowledge, experiences and to celebrate all that has been achieved in the last decade.
The 10th Annual Champalimaud Research Symposium, which took place on 29th January in Hyderabad, was inaugurated by Leonor Beleza, President of the Champalimaud Foundation, and Dr. Gullapalli N. Rao, Chairman of the LV Prasad Eye Institute. In her inaugural speech, besides expressing her deep gratitude for all that is being done by the LVPEI leaders and team, Leonor Beleza also highlighted the importance of collaboration between the scientific community and how perfectly the long-lasting partnership between the Champalimaud Foundation and LVPEI embodies this principle. This strong tie between the two institutions, devised 10 years ago, follows a historical connection between Portugal and India that will certainly extend for many decades to come.
The Champalimaud keynote lecture was delivered by Prof. Joan Miller, Chair of the Department of Ophthalmology, and the Massachusetts Eye and Ear, at Harvard Medical School, Boston, USA, and 2014 António Champalimaud Vision Award Co-recipient. The Symposium included lectures by Dr. Soumya Swaminathan, Director General of the ICMR, India, and Prof. Niyaz Ahmed, Director, International Center for Diarrhoeal Diseases Research, Dhaka, Bangladesh, and the annual update presentation from the scientists and clinicians of the Brien Holden Eye Research Centre, regarding their ongoing research activities supported by the Champalimaud Foundation.
Throughout the Symposium, the remarkable progress accomplished by the C-TRACER partnership was brought to light, namely the advances already made in stem cell therapy, diagnosis and treatment of cancers of the eye and screening and treatment of retinopathy of prematurity. But more than an insight into what is being done, the focus was on what is still to come and the future plans guiding the research and clinical activities.
The scientific programme also included interventions from key players working at the forefront of molecular genetics of ocular disease, visual neurosciences, public health, clinical and molecular microbiology and low vision research.
For 10 years now, we have been witnessing a true revolution in eye care, incubated in the C-TRACER partnership, but that has long-since surpassed its expectations. Each year we are astonished by how much has been accomplished and we can’t wait to find out what 2017 will bring us and the world of vision.